DE69736293D1 - Verfahren und zusammensetzung zur auffindung von cervix-krebs - Google Patents

Verfahren und zusammensetzung zur auffindung von cervix-krebs

Info

Publication number
DE69736293D1
DE69736293D1 DE69736293T DE69736293T DE69736293D1 DE 69736293 D1 DE69736293 D1 DE 69736293D1 DE 69736293 T DE69736293 T DE 69736293T DE 69736293 T DE69736293 T DE 69736293T DE 69736293 D1 DE69736293 D1 DE 69736293D1
Authority
DE
Germany
Prior art keywords
cervical cancer
provides
individual
preparation
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736293T
Other languages
English (en)
Other versions
DE69736293T2 (de
Inventor
K Keesee
Robert Obar
Ying-Jye Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matritech Inc
Original Assignee
Matritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matritech Inc filed Critical Matritech Inc
Publication of DE69736293D1 publication Critical patent/DE69736293D1/de
Application granted granted Critical
Publication of DE69736293T2 publication Critical patent/DE69736293T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DE69736293T 1996-08-30 1997-08-19 Verfahren und zusammensetzung zur auffindung von cervix-krebs Expired - Lifetime DE69736293T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/705,660 US5858683A (en) 1996-08-30 1996-08-30 Methods and compositions for the detection of cervical cancer
PCT/US1997/014526 WO1998009170A2 (en) 1996-08-30 1997-08-19 Methods and compositions for the detection of cervical cancer
US705660 2000-11-03

Publications (2)

Publication Number Publication Date
DE69736293D1 true DE69736293D1 (de) 2006-08-17
DE69736293T2 DE69736293T2 (de) 2007-06-14

Family

ID=24834422

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736293T Expired - Lifetime DE69736293T2 (de) 1996-08-30 1997-08-19 Verfahren und zusammensetzung zur auffindung von cervix-krebs

Country Status (9)

Country Link
US (4) US5858683A (de)
EP (1) EP0923740B1 (de)
JP (1) JP4116082B2 (de)
AT (1) ATE332505T1 (de)
AU (1) AU4073297A (de)
CA (1) CA2263888C (de)
DE (1) DE69736293T2 (de)
ES (1) ES2268735T3 (de)
WO (1) WO1998009170A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1025444B1 (de) * 1997-10-21 2005-03-02 Cancer Research Technology Limited Nachweis von zellwachstumabnormalität
US6303323B1 (en) 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
GB9805477D0 (en) * 1998-03-13 1998-05-13 Oxford Glycosciences Limited Methods and compositions for diagnosis of rheumatoid arthritis
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
DE19855819C2 (de) * 1998-12-03 2001-02-15 Roche Diagnostics Gmbh Stabilisierung von Cytokeratin enthaltenden Kalibratoren
US6294349B1 (en) 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6379970B1 (en) * 1999-04-30 2002-04-30 The Arizona Board Of Regents On Behalf Of The University Of Arizona Analysis of differential protein expression
IL146374A0 (en) 1999-05-17 2002-07-25 Pro Duct Health Inc Identifying material from a breast duct
CA2376831A1 (en) * 1999-06-29 2001-01-04 Intercet, Ltd. Human cancer virtual simulation system
WO2001042467A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2074101A (en) * 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2002021428A1 (en) * 2000-09-01 2002-03-14 Large Scale Proteomics Corporation Reference database
US6980674B2 (en) * 2000-09-01 2005-12-27 Large Scale Proteomics Corp. Reference database
US6539102B1 (en) * 2000-09-01 2003-03-25 Large Scale Proteomics Reference database
EP1202211A3 (de) * 2000-10-26 2004-12-22 Riken Computerprogramm zur Analyse von genomischer DNS
KR100426453B1 (ko) * 2000-11-28 2004-04-13 김진우 인간 자궁경부암 2 원암 유전자 및 이에 의해 코딩되는단백질, 이를 포함하는 발현벡터 및 이 벡터로 형질전환된세포
KR100426454B1 (ko) * 2000-11-28 2004-04-13 김진우 인간 원암 유전자 및 이에 의해 코드되는 단백질
US20030009293A1 (en) * 2001-01-09 2003-01-09 Anderson Norman G. Reference database
AUPR595601A0 (en) 2001-06-27 2001-07-19 International Diabetes Institute Hypoglycaemic peptides and methods of use thereof
KR100472746B1 (ko) * 2001-08-13 2005-03-07 김진우 원암 유전자 ｋｇ-20 및 이에 의해 코드되는 단백질
US20030138425A1 (en) * 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
EP1333278B1 (de) 2002-02-01 2004-03-10 MTM molecular tools in medicine Verfahren zur Prognose gastrointestinaler Tumoren
KR100472747B1 (ko) * 2002-03-12 2005-03-09 김진우 인간 원암 유전자 및 이에 의해 코드되는 단백질
EP1369694A1 (de) * 2002-04-09 2003-12-10 MTM Laboratories AG Verfahren zur Unterscheidung zwischen Metaplasien und neoplastischen oder präneoplastischen Läsionen
DE60229920D1 (de) * 2002-05-21 2009-01-02 Mtm Lab Ag Marker für Lungentumore
KR20030094905A (ko) * 2002-06-10 2003-12-18 김진우 생쥐 발암유전자, 이에 의해 코드되는 단백질 및 이를포함하는 발현벡터
AU2002345407A1 (en) * 2002-06-29 2004-01-19 Jin-Woo Kim Human cervical cancer 5 protooncogene and protein encoded therein
AU2002345414A1 (en) * 2002-07-04 2004-01-23 Jin Woo Kim Human protooncogene 6 and protein encoded therein
ATE261126T1 (de) * 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
EP1422526A1 (de) 2002-10-28 2004-05-26 MTM Laboratories AG Verfahren zur verbesserten Diagnose von Dysplasien
US20040137551A1 (en) * 2003-01-13 2004-07-15 Markovic Nenad S. Cervical acid phosphatase - papanicolaou (CAP-PAP) test kit, method and accesories, processes for producing and using the same
US7291699B2 (en) * 2003-03-18 2007-11-06 The Regents Of The University Of Colorado Product and methods for diagnosis and therapy for cardiac and skeletal muscle disorders
US7361460B2 (en) * 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
ATE289685T1 (de) * 2003-08-25 2005-03-15 Mtm Lab Ag Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
JPWO2005043166A1 (ja) * 2003-10-30 2007-11-29 シスメックス株式会社 子宮腺癌の診断薬及び腺癌細胞の検出方法
WO2005054548A2 (en) 2003-11-28 2005-06-16 Invitrogen Corporation Methods, compositions, and kits for protein crystallization
KR100882249B1 (ko) * 2004-03-24 2009-02-06 트리패스 이미징, 인코포레이티드 자궁경부 질환의 검사 방법 및 조성물
EP1586903A1 (de) * 2004-03-30 2005-10-19 Sysmex Corporation Methode zum Screenen nach Zervixkarzinomen
US7183057B2 (en) * 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
US7316904B1 (en) 2004-06-30 2008-01-08 Chromodynamics, Inc. Automated pap screening using optical detection of HPV with or without multispectral imaging
EP1835929B8 (de) 2005-01-06 2016-07-27 Novo Nordisk A/S Behandlungen und verfahren mit anti-kir-kombination
KR100689275B1 (ko) 2005-03-30 2007-03-08 김현기 인간 원암유전자 ｔｒｇ 및 이에 의해 코드되는 단백질
US7595380B2 (en) * 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
US20070015166A1 (en) * 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
US7632498B2 (en) * 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
WO2009015294A1 (en) 2007-07-24 2009-01-29 Wisconsin Alumni Research Foundation Biomarkers for human papillomavirus-associated cancers
JP2011520451A (ja) 2008-05-14 2011-07-21 ダームテック インターナショナル 核酸解析による黒色腫および日光黒子の診断法
US10011884B2 (en) 2010-11-12 2018-07-03 Incelldx, Inc. Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
CN105899673B (zh) * 2013-08-08 2019-09-13 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白
WO2016014939A1 (en) 2014-07-24 2016-01-28 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
KR20180132807A (ko) * 2016-04-07 2018-12-12 케이스 웨스턴 리저브 유니버시티 신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제
US11352436B2 (en) 2017-02-10 2022-06-07 Washington University Antibodies to TIP1 and methods of use thereof
WO2020198229A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
DE3588043T2 (de) * 1984-01-06 1996-03-21 Univ California Cytokeratin-tumormarkierer und test zu deren nachweis.
JPS6284100A (ja) * 1985-10-08 1987-04-17 Dainabotsuto Kk 扁平上皮癌関連抗原に対する抗体及びその免疫学的利用法
US4882268A (en) * 1985-12-24 1989-11-21 Massachusetts Institute Of Technology Method for determining tissue of origin and degree of malignancy of tumor cells
US5273877A (en) * 1985-12-24 1993-12-28 Massachusetts Institute Of Technology Non-histological cell type determination
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
CA1340245C (en) * 1989-04-21 1998-12-15 John Samuel Monoclonal antibody for differentiation of squamous cell carcinoma antigens and method of use for same
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
JP3190042B2 (ja) * 1991-10-31 2001-07-16 マトリテク インコーポレイテッド 核マトリックス蛋白液アッセー
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
US5350835A (en) * 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
WO1994000573A1 (en) * 1992-06-22 1994-01-06 Matritech, Inc. Novel malignant cell type markers of the interior nuclear matrix
AU5694694A (en) * 1992-12-02 1994-06-22 Denis F. Hochstrasser A method for detecting growing cells using translationally controlled tumor protein p21
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
US5519003A (en) * 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof

Also Published As

Publication number Publication date
US6027905A (en) 2000-02-22
WO1998009170A3 (en) 1998-04-23
CA2263888C (en) 2004-10-26
ATE332505T1 (de) 2006-07-15
WO1998009170A2 (en) 1998-03-05
AU4073297A (en) 1998-03-19
US20030157482A1 (en) 2003-08-21
JP2001500609A (ja) 2001-01-16
EP0923740A2 (de) 1999-06-23
EP0923740B1 (de) 2006-07-05
US20050164313A1 (en) 2005-07-28
CA2263888A1 (en) 1998-03-05
US6803189B2 (en) 2004-10-12
ES2268735T3 (es) 2007-03-16
US5858683A (en) 1999-01-12
DE69736293T2 (de) 2007-06-14
JP4116082B2 (ja) 2008-07-09

Similar Documents

Publication Publication Date Title
DE69736293D1 (de) Verfahren und zusammensetzung zur auffindung von cervix-krebs
DE60033555D1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
EP1379693A4 (de) Auf oligonukleotid-modifizierten partikeln basierende bio-strichcodes
ES2182297T3 (es) Deteccion y modulacion de lo inhibidores de las proteinas de la apoptosis (iaps) y de los polipeptidos anti-apoptoticos afines (naip) para la diagnosis y tratamiento de enfermedades proliferativas.
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
DE60118527D1 (de) Sensible und multiplexe diagnostische tests zur proteinanalyse
ATE437369T1 (de) Enzymkatalysierte metalldeposition zum verstärkten in-situ-nachweis von immunhistologischen epitopen und nukleinsäuresequenzen
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
WO1995016919A3 (en) Methods and compositions for the detection of colon cancers
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
ATE418072T1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
FR2660757B1 (fr) Procede d'identification ou de dosage de proteines et applications.
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
DE59813433D1 (de) Aufreinigung von substanzen aus einer biologischen probe
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DE60138192D1 (de) Verfahren zur quantifizierung der akt-protein-expression
Terao et al. Cross-linking of L5 protein to 5 S RNA in rat liver 60-S subunits by ultraviolet irradiation
DE69941690D1 (de) Methoden, testsätze und kompositionen zur detektion und quantifizierung von zielsequenzen
WO2002078636A3 (en) Detection and treatment of colorectal cancer
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
WO2002075314A8 (en) Detection and treatment of prostate cancer
ATE272718T1 (de) Verfahren zur bestimmung von disaccharidasen
DK1423708T3 (da) Sammensætninger og fremgangsmåder til bestemmelser af AA4RP

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MATRITECH, INC. (N.D.GES.D. STAATES DELAWARE),, US